← Leaderboards
Jay O Boyle
Sloan-Kettering Institute For Cancer Res
$420,309
Attributed
$420,309
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $209.4K · FY2005–06$250K$187.5K$125K$62.5K$0
'05
'06
Funding mix
By agency
NIH$420,309 · 2
By mechanism
R21$289,999 · 1
R03$130,310 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Richard J O'Reilly$17,498,839
- Lorraine J Gudas$39,938,263
- Neal Rosen$21,048,001
- Philip O. Livingston$8,464,484
- Marcel R M Van Den Brink$40,856,878
Others in their field
Top investigators on “Nonsteroidal Antiinflammatory Agent”
- James N Weinstein · Dartmouth College$13,929,101
- Kathleen Anne Welsh-Bohmer · Duke University$8,270,677
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$6,868,209
- Allen A Mitchell · Boston University Medical Campus$5,287,973
- Claudia H. Kawas · Johns Hopkins University$4,649,398
- Jenny T Mao · Va San Diego Healthcare System$3,842,900
Research focus
Nonsteroidal Antiinflammatory AgentDrug Screening /EvaluationData Collection Methodology /EvaluationProstaglandin Endoperoxide SynthaseDrug Design /Synthesis /ProductionClinical ResearchClinical Trial Phase IiClinical TrialsExperimental DesignsGenetic PolymorphismHuman SubjectHuman Therapy EvaluationIndiaInternational CooperationMolecular GeneticsNeoplasm /Cancer EpidemiologyOral LeukoplakiaOral Pharyngeal NeoplasmOxidoreductase InhibitorP53 Gene /ProteinPharmacologyPreneoplastic StateAlcoholism /Alcohol AbuseUnited States
Grant awards (4)
Phase II Study of Sulindac in Oral Premalignant Lesions$64,960
R03 · FY2006 · CA · contact PI
Planning a Trial of Sulindac for Oral Leukoplakia$144,069
R21 · FY2005 · DE
Phase II Study of Sulindac in Oral Premalignant Lesions$65,350
R03 · FY2005 · CA
Planning a Trial of Sulindac for Oral Leukoplakia$145,930
R21 · FY2004 · DE